BridgeMD
Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
EU CTIS ID: 2025-521154-42-00
What this study is testing
The primary objective of this study is to assess the safety of anumigilimab in adults with SCD
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults aged greater than or equal to (>=) 18 years on the day of signing the informed consent form.
- Confirmed diagnosis of SCD of any genotype.
- Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening.
- HU Regimen: a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening. or b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect).
You likely can't join if
- Absolute neutrophil count less than (<) 2.5 ×10^9 cells/Litre at Screening or Baseline (Week 1 Day 1).
- If on SCD preventive medication, dose is not stable in the 30 days before Screening.
- History of myeloproliferative disorder or malignancy (other than skin cancer) within 5 years before Screening.
- History of stem cell transplant or gene therapy.
- Hemoglobin < 6.5 g/dL at Screening or Baseline (Week 1 Day 1).
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Saudi Arabia
- Turkey
- Canada
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Saudi Arabia; Turkey; Canada; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.